Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis

Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study

(2016) Michael D Tarantino et al.   LANCET

A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP

(2015) H. Zhou et al.   BLOOD

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial

(2015) John D Grainger et al.   LANCET

Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study

(2015) James B Bussel et al.   Lancet Haematology

Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia

(2013) Michael D. Tarantino et al.   BLOOD COAGULATION & FIBRINOLYSIS

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

(2013) David J. Kuter et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care

(2012) Roberto Stasi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia

(2012) Shujie Wang et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia

(2012) Y. TOMIYAMA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Romiplostim in children with chronic refractory ITP: randomized placebo controlled study

(2011) Mohsen Saleh Elalfy et al.   ANNALS OF HEMATOLOGY

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia

(2011) J. B. Bussel et al.   BLOOD

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

(2011) C. Neunert et al.   BLOOD

Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial

(2011) Yukari Shirasugi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)

(2010) T. B. GERNSHEIMER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

(2010) Gregory Cheng et al.   LANCET

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

(2010) David J. Kuter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim

(2009) D. J. Kuter et al.   BLOOD

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

(2009) James B Bussel et al.   LANCET

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET